Reoviruses having modified sequences
AssigneeOncolytics Biotech Inc.
InventorMatthew C Coffey
Life of this patent
Estimating the term…
Abstract
The invention provides for modified reovirus nucleic acid sequences and modified reovirus polypeptide sequences as well as reoviruses containing such modified nucleic acid or polypeptide sequences. The invention also provides for pharmaceutical compositions that include reoviruses having a modified sequence as well as methods of making and using such reoviruses.
Claims20
An isolated reovirus comprising one or more of the following polypeptides:
- a) a sigma-3 polypeptide comprising SEQ ID NO:15;
- b) a mu-1 polypeptide having at least one amino acid modification, wherein the at least one amino acid modification comprises an Asp at residue 73 numbered relative to SEQ ID NO:27 (GenBank Accession No. M20161.1);
- or
- c) a mu-2 polypeptide having at least one amino acid modification, wherein the at least one amino acid modification comprises a Ser at residue 528 numbered relative to SEQ ID NO:29 (GenBank Accession No. AF461684.1).
An isolated reovirus comprising one or both of the following genome segments:
- a) a S4 genome segment comprising SEQ ID NO:4;
- or
- b) a M2 genome segment having at least one nucleic acid modification, wherein the at least one nucleic acid modification comprises a C at position 248, numbered relative to SEQ ID NO:26 (GenBank Accession No. M20161.1).
An isolated reovirus comprising a M1 genome segment, wherein the M1 genome segment comprises SEQ ID NO:5.
An isolated polypeptide selected from the group consisting of:
- a) a polypeptide comprising an amino acid sequence of a reovirus sigma-3 polypeptide, wherein the sequence of the reovirus sigma-3 polypeptide comprises SEQ ID NO:15;
- b) a polypeptide comprising an amino acid sequence of a reovirus mu-1 polypeptide, wherein the sequence of the reovirus mu-1 polypeptide comprises at least one amino acid modification, wherein the at least one amino acid modification comprises an Asp at residue 73 numbered relative to SEQ ID NO:27 (GenBank Accession No. M20161.1);
- and
- c) a polypeptide comprising an amino acid sequence of a reovirus mu-2 polypeptide, wherein the sequence of the reovirus mu-2 polypeptide comprises at least one amino acid modification, wherein the at least one amino acid modification comprises a Ser at residue 528 numbered relative to SEQ ID NO:29 (GenBank Accession No. AF461684.1).
An isolated nucleic acid molecule selected from the group consisting of:
- a) a nucleic acid molecule comprising a nucleic acid sequence of a reovirus S4 genome segment, wherein the nucleic acid sequence of the reovirus S4 genome segment comprises SEQ ID NO:4;
- and
- b) a nucleic acid molecule comprising a nucleic acid sequence of a reovirus M2 genome segment, wherein the nucleic acid sequence of the reovirus M2 genome segment comprises at least one nucleic acid modification, wherein the at least one nucleic acid modification comprises a C at position 248, numbered relative to SEQ ID NO:
- 26 (GenBank Accession No. M20161.1).
An isolated nucleic acid molecule comprising a nucleic acid sequence of a reovirus M2 genome segment, wherein the M2 genome segment comprises SEQ ID NO:6.
Dependencies are inferred from the claim text.